A5054335250- Angiogenesis and VEGF in Cancer
- Cancer Immunotherapy and Biomarkers
- Atherosclerosis and Cardiovascular Diseases
- Immune cells in cancer
- Cell Adhesion Molecules Research
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Quinazolinone synthesis and applications
- Cancer, Hypoxia, and Metabolism
- PI3K/AKT/mTOR signaling in cancer
- Melanoma and MAPK Pathways
- Neuroblastoma Research and Treatments
- Neuroendocrine Tumor Research Advances
- Cytokine Signaling Pathways and Interactions
- CAR-T cell therapy research
Columbia University Irving Medical Center
2023-2024
Seoul National University
2018-2021
Cancer Research Institute of the Slovak Academy of Sciences
2016
Major histocompatibility complex (MHC) class I downregulation is the primary immune evasion mechanism associated with failure in anti-PD-1/PD-L1 blockade therapies for cancer. Here, we examined role of MEK signaling pathway inhibition head and neck squamous cell carcinoma (HNSCC) both vitro vivo. We found that trametinib, a small molecule inhibitor MEK, significantly enhanced MHC PD-L1 expression human HNSCC lines, this occurred via STAT3 activation. Trametinib also further upregulated...
Abstract T-cell position in the tumor microenvironment determines probability of target encounter and killing. CD8+ exclusion from parenchyma is associated with poor response to immunotherapy, yet biology that underpins this distinct pattern remains unclear. Here we show vascular destabilizing factor angiopoietin-2 (ANGPT2) causes compromised integrity periphery, leading impaired infiltration core. The spatial regulation ANGPT2 whole cross-sections was analyzed conjunction distribution,...
Improving the management of metastasis in pancreatic neuroendocrine tumors (PanNETs) is critical, as nearly half patients with PanNETs present liver metastases, and this accounts for majority patient mortality. We identified angiopoietin-2 (ANGPT2) one most upregulated angiogenic factors RNA-Seq data from human PanNET metastases found that higher ANGPT2 expression correlated poor survival rates. Immunohistochemical staining revealed was localized to endothelial cells blood vessels...
Abstract Immune checkpoint inhibitors (ICIs), which prevent immune cell exhaustion and boost an antitumor response, have shown remarkable treatment efficacy in patients with advanced melanoma. However, its is limited by the emergence of resistance associated immunosuppressive tumor microenvironment (TME). The contribution abnormal vasculature to infiltration into core has been reported but mechanisms development are still elusive. We analyzed how angiogenesis affects exclusion at different...
<p>Supplemental Figures and Tables</p>
<div>Abstract<p>T cell position in the tumor microenvironment determines probability of target encounter and killing. CD8+ T exclusion from parenchyma is associated with poor response to immunotherapy, yet biology that underpins this distinct pattern remains unclear. Here we show vascular destabilizing factor angiopoietin-2 (ANGPT2) causes compromised integrity periphery, leading impaired infiltration core. The spatial regulation ANGPT2 whole cross-sections was analyzed...
<p>Supplemental Figures and Tables</p>
<div>Abstract<p>T cell position in the tumor microenvironment determines probability of target encounter and killing. CD8+ T exclusion from parenchyma is associated with poor response to immunotherapy, yet biology that underpins this distinct pattern remains unclear. Here we show vascular destabilizing factor angiopoietin-2 (ANGPT2) causes compromised integrity periphery, leading impaired infiltration core. The spatial regulation ANGPT2 whole cross-sections was analyzed...
<div>Abstract<p>T-cell position in the tumor microenvironment determines probability of target encounter and killing. CD8<sup>+</sup> T-cell exclusion from parenchyma is associated with poor response to immunotherapy, yet biology that underpins this distinct pattern remains unclear. Here we show vascular destabilizing factor angiopoietin-2 (ANGPT2) causes compromised integrity periphery, leading impaired infiltration core. The spatial regulation ANGPT2 whole...
<p>Supplemental Figures and Tables</p>
<p>Supplemental Figures and Tables</p>
Abstract T-cell position in the tumor microenvironment determines probability of target encounter and killing. CD8+ exclusion from parenchyma is associated with poor response to immunotherapy yet biology that underpins this distinct pattern remains unclear. Here we show vascular destabilizing factor angiopoietin-2 (ANGPT2) causes compromised integrity periphery, leading impaired infiltration within tumor. We analyzed spatial regulation ANGPT2 whole cross-sections its impact on position,...
<div>Abstract<p>T-cell position in the tumor microenvironment determines probability of target encounter and killing. CD8<sup>+</sup> T-cell exclusion from parenchyma is associated with poor response to immunotherapy, yet biology that underpins this distinct pattern remains unclear. Here we show vascular destabilizing factor angiopoietin-2 (ANGPT2) causes compromised integrity periphery, leading impaired infiltration core. The spatial regulation ANGPT2 whole...
<p>Supplemental Figures and Tables</p>
<p>Supplemental Figures and Tables</p>